Abstract: The current invention relates to high-affinity antibodies to EphA3 that have reduced immunogenicity when administered to a human to treat diseases and method of using such antibodies.
Type:
Grant
Filed:
December 30, 2013
Date of Patent:
March 22, 2016
Assignee:
KaloBios Pharmaceuticals, Inc.
Inventors:
Kenneth Luehrsen, David Martinez, Christina Yi, Christopher R. Bebbington, Geoffrey T. Yarranton
Abstract: The present invention is directed generally to compositions and methods for obtaining secretion of antibodies or antigen-binding antibody fragments from prokaryotes without the need for a signal peptide through making use of mutant host strains with altered secretory properties. In particular, the invention provides host cells and methods for obtaining secretion of antibodies or antigen-binding antibody fragments from bacteria without the need for a signal peptide and provides diverse libraries of antibody sequence resulting from such methods. The invention additionally provides diverse libraries.
Type:
Grant
Filed:
May 7, 2012
Date of Patent:
September 8, 2015
Assignee:
KaloBios Pharmaceuticals, Inc.
Inventors:
Geoffrey T. Yarranton, Christopher R. Bebbington
Abstract: The invention provides anti-EGF-like module containing, mucin-like, hormone receptor-like 1 (EMR1) antibodies and methods of using such antibodies to treat EMR1-related diseases.
Type:
Grant
Filed:
May 25, 2012
Date of Patent:
June 2, 2015
Assignee:
Kalobios Pharmaceuticals, Inc.
Inventors:
Kenneth Luehrsen, Mark Baer, Christopher R. Bebbington, David Martinez, Varghese Palath, Swathi Sujatha-Bhaskar, Nenad Tomasevic, Jason Williams, Geoffrey T. Yarranton
Abstract: The current invention relates to high-affinity antibodies to Granulocyte-Macrophage Colony-Stimulating Factor that have reduced immunogenicity when administered to a human to treat diseases and method of using such antibodies.
Type:
Grant
Filed:
April 30, 2012
Date of Patent:
April 28, 2015
Assignee:
KaloBios Pharmaceuticals, Inc.
Inventors:
Christopher R. Bebbington, Kenneth Luehrsen, Geoffrey Yarranton
Abstract: The current invention provides high-affinity antibodies to the Pseudomonas aeruginosa PcrV protein that have reduced immunogenicity when administered to treat Pseudomonas aeruginosa infections.
Type:
Grant
Filed:
October 11, 2011
Date of Patent:
November 4, 2014
Assignee:
KaloBios Pharmaceuticals, Inc.
Inventors:
Christopher R. Bebbington, Kenneth Luehrsen, Geoffrey T. Yarranton, Mark Baer
Abstract: The current invention relates to high-affinity antibodies to EphA3 that have reduced immunogenicity when administered to a human to treat diseases and method of using such antibodies.
Type:
Application
Filed:
December 30, 2013
Publication date:
May 1, 2014
Applicant:
KALOBIOS PHARMACEUTICALS, INC.
Inventors:
Kenneth Luehrsen, David Martinez, Christina Yi, Christopher R. Bebbington, Geoffrey T. Yarranton
Abstract: The current invention relates to high-affinity antibodies to EphA3 that have reduced immunogenicity when administered to a human to treat diseases and method of using such antibodies.
Type:
Grant
Filed:
October 14, 2010
Date of Patent:
March 4, 2014
Assignee:
KaloBios Pharmaceuticals, Inc.
Inventors:
Kenneth Luehrsen, David Martinez, Christina Yi, Christopher R. Bebbington, Geoffrey T. Yarranton
Abstract: This invention provides methods of treating patients having a Staphylococcus infection where the patient also has a low level of Pseudomonas aeruginosa. The methods comprise administering an antagonist of the Pseudomonas Type III Secretion System, e.g., an anti-PcrV antibody antagonist.
Abstract: The invention is based on the discovery that GM-CSF antagonists can be used for the treatment of a patient that has Alzheimer's disease or vascular dementia, or is at risk for developing Alzheimer's disease. Accordingly, the invention provides methods of administering a GM-CSF antagonist, e.g., a GM-CSF antibody and pharmaceutical compositions comprising such antagonists.
Abstract: The invention is based on the discovery that GM-CSF antagonists can be used for the treatment of a patient that has Alzheimer's disease or vascular dementia, or is at risk for developing Alzheimer's disease. Accordingly, the invention provides methods of administering a GM-CSF antagonist, e.g., a GM-CSF antibody and pharmaceutical compositions comprising such antagonists.
Type:
Grant
Filed:
February 11, 2010
Date of Patent:
March 19, 2013
Assignee:
KaloBios Pharmaceuticals, Inc.
Inventors:
Christopher R. Bebbington, Geoffrey T. Yarranton, Varghese Palath
Abstract: The present invention is directed generally to compositions and methods for expressing recombinant proteins in a mammalian host cell using a co-expressed transcriptional activator. In particular, the invention provides vectors, host cells, and methods of expressing at least one desired polypeptide by transfecting a mammalian host cell with cistrons encoding a transactivator, a desired polypeptide, and an apoptosis-protective protein.
Abstract: The present invention is directed generally to compositions and methods for obtaining secretion of antibodies or antigen-binding antibody fragments from prokaryotes without the need for a signal peptide through making use of mutant host strains with altered secretory properties. In particular, the invention provides host cells and methods for obtaining secretion of antibodies or antigen-binding antibody fragments from bacteria without the need for a signal peptide and provides diverse libraries of antibody sequence resulting from such methods. The invention additionally provides diverse libraries.
Type:
Application
Filed:
May 7, 2012
Publication date:
December 6, 2012
Applicant:
KaloBios Pharmaceuticals Inc.
Inventors:
Geoffrey T. Yarranton, Christopher R. Bebbington
Abstract: The current invention relates to high-affinity antibodies to Granulocyte-Macrophage Colony-Stimulating Factor that have reduced immunogenicity when administered to a human to treat diseases and method of using such antibodies.
Type:
Application
Filed:
April 30, 2012
Publication date:
August 23, 2012
Applicant:
KaloBios Pharmaceuticals, Inc.
Inventors:
Christopher R. Bebbington, Kenneth Luehrsen, Geoffrey T. Yarranton
Abstract: The present invention is directed generally to compositions and methods for obtaining secretion of antibodies or antigen-binding antibody fragments from prokaryotes without the need for a signal peptide through making use of mutant host strains with altered secretory properties. In particular, the invention provides host cells and methods for obtaining secretion of antibodies or antigen-binding antibody fragments from bacteria without the need for a signal peptide and provides diverse libraries of antibody sequence resulting from such methods. The invention additionally provides diverse libraries.
Type:
Grant
Filed:
November 14, 2005
Date of Patent:
July 3, 2012
Assignee:
KaloBios Pharmaceuticals, Inc.
Inventors:
Geoffrey T. Yarranton, Christopher R. Bebbington
Abstract: The current invention relates to high-affinity antibodies to Granulocyte-Macrophage Colony-Stimulating Factor that have reduced immunogenicity when administered to a human to treat diseases and method of using such antibodies.
Type:
Grant
Filed:
April 28, 2009
Date of Patent:
May 1, 2012
Assignee:
KaloBios Pharmaceuticals, Inc.
Inventors:
Christopher R. Bebbington, Kenneth Luehrsen, Geoffrey T. Yarranton